Breakdown |
---|
Income Statement |
Total Revenue |
Gross Profit |
EBITDA |
Net Income |
Balance Sheet |
Total Assets |
Cash, Cash Equivalents and Short-Term Investments |
Total Debt |
Total Liabilities |
Stockholders Equity |
Cash Flow |
Free Cash Flow |
Operating Cash Flow |
Investing Cash Flow |
Financing Cash Flow |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.46B | -0.16 | -46.00% | 2.25% | 22.82% | -2.28% | |
49 Neutral | $8.94M | ― | -72.70% | ― | 5.05% | 26.13% | |
47 Neutral | $71.55M | ― | -68.84% | ― | -7.81% | 65.39% | |
45 Neutral | $8.95M | ― | -63.40% | ― | -91.14% | 9.47% | |
45 Neutral | $57.81M | ― | -230.80% | ― | -16.46% | 4.16% | |
37 Underperform | $25.00 | ― | ― | -2.99% | 59.87% | ||
29 Underperform | $1.96M | ― | -96.69% | ― | ― | 98.25% |
On May 8, 2025, Accelerate Diagnostics, Inc. and its US subsidiary filed for Chapter 11 bankruptcy protection, initiating a sale process for substantially all of its assets. The company entered into an asset purchase agreement with Indaba Capital Management, its secured noteholder, to sell its assets, subject to court approval and competitive bidding procedures. This move is part of a strategic effort to manage its financial obligations and is expected to significantly impact stakeholders, with the company cautioning that common stockholders may face substantial losses.
On May 21, 2025, David Patience announced his resignation as Chief Financial Officer of Accelerate Diagnostics, effective June 30, 2025, to pursue other professional opportunities. His departure is not due to any disagreements with the company’s operations or policies, suggesting a smooth transition and stability in the company’s management.